The abnormal immune function of tumor patients and the existence of AXL-related tumor neoantigens suggested that there might be potential risks in the application of AXL-related tumor vaccines or SARS-Cov-2 vaccines in patients. The gene discussed is AXL; the disease is neoplasm.